NYSE:PEN Penumbra Q3 2026 Earnings Results & Report $321.68 +3.37 (+1.06%) Closing price 03:59 PM EasternExtended Trading$321.86 +0.18 (+0.06%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Penumbra missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released October 29, 2026. The company reported EPS of $1.07 versus the $1.20 consensus estimate, while revenue of $410.15 million topped the $401.41 million estimate by $8.74 million. Revenue increased 15.6% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 29, 2026TimeAfter Market ClosesConference Call4:00 PM ET Penumbra EPS ResultsActual EPS$1.07Consensus EPS $1.20Beat/MissMissed by -$0.13One Year Ago EPS$0.97EPS Beat Rate4 of last 8 quartersPenumbra Revenue ResultsActual Revenue$410.15 millionExpected Revenue$401.41 millionBeat/MissBeat by +$8.74 millionYoY Revenue Growth+15.60%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Penumbra Q3 2026 Earnings FAQ Did Penumbra beat earnings estimates for Q3 2026? Penumbra (NYSE:PEN) reported earnings of $1.07 per share for Q3 2026, missing the consensus estimate of $1.20. The report was announced on Thursday, October 29, 2026. What was Penumbra's revenue for Q3 2026? Penumbra reported revenue of $410.15 million for Q3 2026, against a consensus estimate of $401.41 million. Penumbra Earnings HeadlinesPenumbra Inc. Q3 Income Drops3 hours ago | rttnews.comPenumbra, Inc. Reports Third Quarter 2026 Financial ResultsOctober 29 at 4:05 PM | prnewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 29 at 1:00 AM | Weiss Ratings (Ad)Penumbra, Inc Receives FDA Clearance For Lightning Computer Assisted Vacuum Thrombectomy Technology For The Treatment Of Deep Vein ThrombosisOctober 21, 2026 | marketscreener.comMPenumbra, Inc.: Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)October 20, 2026 | finanznachrichten.dePenumbra Says FDA Clears CAVT Technology for Deep Vein ThrombosisOctober 20, 2026 | finance.yahoo.comSee More Penumbra Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email. Email Address About PenumbraPenumbra (NYSE:PEN) is a medical device company that develops, manufactures and markets products used to treat patients with vascular conditions. Its technologies are primarily designed for minimally invasive procedures in the neurovascular and peripheral vascular markets, including the treatment of ischemic stroke, brain aneurysms and other vascular disorders. The company’s product portfolio includes aspiration and mechanical thrombectomy systems for removing blood clots, embolization devices for blocking abnormal blood flow, and access and delivery products used during endovascular procedures. Penumbra also offers the Indigo System, which is used to remove thrombus from vessels outside the brain, as well as products for treating vascular malformations and other conditions. Founded in 2004, Penumbra is headquartered in Alameda, California. The company serves healthcare providers internationally through direct operations and distribution relationships across markets in North America, Europe, Asia-Pacific and other regions. Adam Elsesser is Penumbra’s co-founder and chief executive officer.View Penumbra ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
